Research programme: L-nucleoside conjugates - OncoVista

Drug Profile

Research programme: L-nucleoside conjugates - OncoVista

Alternative Names: b-L-dU/b-D-5FUdR

Latest Information Update: 15 Jul 2011

Price : $50

At a glance

  • Originator Genencor International; Lipitek International
  • Developer OncoVista
  • Class Drug conjugates; Nucleosides
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Jul 2011 Preclinical trials in Cancer in USA (IV)
  • 17 Jan 2008 OVI 117 is undergoing GLP animal drug safety studies
  • 06 Dec 2005 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top